Therapeutic Solutions International

CA - OceansideBiotechnology1 H-1B visas (FY2023)

Focus: Therapeutic Solutions International is a mid-cap biotech company headquartered in Oceanside, CA, focused on cell therapy and gene therapy with a portfolio anchored by ADHD treatments and a nascent pipeline in rare genetic diseases.

Gene Therapy Cell Therapy

Profile data last refreshed 9h ago · AI intelligence enriched 1w ago

Open Jobs

About Therapeutic Solutions International

AI assessmentNot Hiring

No open roles listed right now. Follow Therapeutic Solutions International to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

ADZENYS XR-ODT

ADHD in patients ≥6 years

$1M Part D

Peak5.9yr

Anchor product generating 83% of company revenue; extended-release ODT formulation provides differentiation but faces generic competition post-LOE.

Help build intelligence for Therapeutic Solutions International

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Established revenue base with two peak-stage ADHD products (ADZENYS XR-ODT and COTEMPLA XR-ODT) providing near-term cash flow stability through 2032–2038.
Pipeline entry into high-impact therapeutic areas: NS-065/NCNP-01 in Phase 2 for Duchenne Muscular Dystrophy represents exposure to rare disease development.
Specialization in cell and gene therapy modalities aligns with growing investor and clinical interest in regenerative medicine.

Watch Out For

Extreme revenue concentration (83% on one product) creates material restructuring risk if ADZENYS XR-ODT faces competitive pressure or regulatory setback before 2032.
Minimal current hiring (0 active job openings) and absent financial data suggest limited hiring velocity and unclear cash runway or growth trajectory.
Early-stage pipeline (only Phase 2 programs, no Phase 3 data) with sparse trial activity (5 total trials) and experimental programs (Kaihani Score, Campbell Score, QuadraMune) of unclear regulatory path.

Generated by Claude from Therapeutic Solutions International's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

COTEMPLA XR-ODT

ADHD

$237K Part D

Peak11.5yr

Secondary ADHD franchise with later LOE (2038) providing revenue visibility beyond ADZENYS exclusivity cliff.

NAPROXEN SODIUM

Rheumatoid arthritis

Post-LOE

Mature generic NSAID past loss of exclusivity; likely minimal revenue contributor.

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX

Post-LOE

Opioid-combination product in mature/post-LOE stage with minimal commercial relevance.